• Email
  • Help

Orphan designation

On 2 October 2013, orphan designation (EU/3/03/131) was granted by the European Commission to Gene Signal SAS, France, for antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the treamtne of neovascular glaucoma.

Key facts

Product details for <p>Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)</p>
Active substanceAntisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)
Medicine Name
Disease/conditionTreatment of neovascular glaucoma
Date of decision02/10/2003
Orphan decision numberEU/3/03/161

Review of designation

Sponsor's contact details

Gene Signal SAS

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.